BIBW 2948Alternative Names: BIBW-2948; BIBW2948 BS
Latest Information Update: 07 Oct 2014
At a glance
- Originator Boehringer Ingelheim
- Class Antiasthmatics; Antibronchitics
- Mechanism of Action Epidermal growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bronchitis; Chronic obstructive pulmonary disease